DIRS.INFO The most relevant business & tech news

☆ Danaher shares jump 7% as the turnaround in biotech spending finally arrives
▼ + stars: | 2024-04-23 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Shares of Danaher popped more than 7% on Tuesday after the life sciences company delivered beats across its three main businesses — a sign the long-awaited turnaround in the biotech industry is finally here. Danaher Why we own it : Danaher is a best-in-class life sciences and diagnostics company, with a management team who have proven time and again their ability to find new ways to grow. The turnaround is now in effect, with bioprocessing orders up on a sequential basis. Within the segment, bioprocessing sales fell a "high teens" percentage, while discovery and medical declined 20% year over year. Diagnostics sales advanced 7.5% on a core basis to $2.53 billion.

Persons: Danaher, Blair, Beckman Coulter, Jim Cramer's, Jim Cramer, Jim, Igor Golovnov Organizations: LSEG, Bloomberg, Biotechnology, Management, CNBC, Getty Locations: bioprocessing, China, North America, Europe

☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
▼ + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.

Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration

☆ Scotland Pauses Gender Medications for Minors
▼ + stars: | 2024-04-18 | by ( Azeen Ghorayshi | ) www.nytimes.com time to read: 1 min

Scotland’s National Health Service has stopped all new prescriptions of puberty-blocking drugs and other hormone treatments for minors, citing a sweeping review of youth gender services released in England last week. It is the sixth country in Europe to limit such treatments, and its changes are among the most restrictive. England and carried out by Dr. Hilary Cass, an independent pediatrician, over the course of four years, concluded that the evidence for benefits of youth gender treatments was “remarkably weak” and that pressing questions remained about potential long-term risks. This month, following recommendations by Dr. Cass, N.H.S. Hormone therapies, including estrogen and testosterone, are still available to teenagers in England aged 16 and up.

Persons: Hilary Cass, . Cass Organizations: Health Service, N.H.S Locations: England, Europe, N.H.S

☆ The Question of Transgender Care - The New York Times
▼ + stars: | 2024-04-18 | by ( David Brooks | ) www.nytimes.com time to read: +2 min

It is about what the health care approach should be, and how best to help the growing number of children and young people who are looking for support from the N.H.S. For reasons that are also not clear, adolescents who were assigned female at birth are driving this trend, whereas before the late 2000s, it was mostly adolescents who were assigned male at birth who sought these treatments. One is that greater social acceptance of trans people has enabled people to seek these therapies. A third is that the rise of teen mental health issues may be contributing to gender dysphoria. In her report, Cass is skeptical of broad generalizations in the absence of clear evidence; these are individual children and adolescents who take their own routes to who they are.

Persons: Hilary Cass, Cass Organizations: National Health Service, Britain’s Royal College of Pediatrics, Child Locations: England, Cass

Luxury trains in India date back to its colonial era, when opulent carriages transported dignitaries, officials and royalty. Without the money to maintain them, India's luxury rail carriages were abandoned. Blending historical elegance with modern comforts, these trains are a glimpse into India's regal past. A peek inside a dining car and a cabin show the ornate details on board India's Palace on Wheels train. Indian food served in one of the dining cars on board the luxury Maharajas' Express.

Persons: —, Sergi Reboredo Organizations: Railways, Local, The Times, Vw, Getty Locations: India, Delhi, Jaipur, Agra, Rajasthan, India Price, South India, Mysore, Bengaluru, Mumbai, Delhi Price

☆ This biotech stock specializing in targeted cancer treatments can surge 50%, Jefferies says
▼ + stars: | 2024-04-17 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Nuvalent could be a winning biotech in the world of cancer treatments, according to Jefferies. Analyst Roger Song initiated the clinical-stage biopharmaceutical company with a buy rating and $97 price target, which implies 49.8% potential upside for shares over the next 12 months. "NUVL leverages strong expertise in structure-based chemistry and deep understanding of unmet [patient] needs to develop potentially 'best-in-class' small molecule targeted cancer therapy," Song wrote in a Wednesday note. "We think both candidates poise well in later line and have strong potential to move into frontline treatments." The company posted a fourth-quarter loss that was slightly wider than expected, at 62 cents per share.

Persons: Roger Song, Jefferies Organizations: Jefferies, U.S . Food, Drug Administration, FactSet Locations: U.S

☆ Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs
▼ + stars: | 2024-04-15 | by ( Christina Jewett | ) www.nytimes.com time to read: +1 min

A Chinese company targeted by members of Congress over potential ties to the Chinese government makes blockbuster drugs for the American market that have been hailed as advances in the treatment of cancers, obesity and debilitating illnesses like cystic fibrosis. WuXi AppTec is one of several companies that lawmakers have identified as potential threats to the security of individual Americans’ genetic information and U.S. intellectual property. A Senate committee approved a bill in March that aides say is intended to push U.S. companies away from doing business with them. The Congressional spotlight on the company has rattled the pharmaceutical industry, which is already struggling with widespread drug shortages now at a 20-year high. Some biotech executives have pushed back, trying to impress on Congress that a sudden decoupling could take some drugs out of the pipeline for years.

Organizations: New York Times Locations: WuXi, U.S

☆ Biotech stocks are ready to break out. They just need one more thing
▼ + stars: | 2024-04-10 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. Last week, Morgan Stanley analysts noted that it is the months leading up to an initial rate cut when biotech stocks outperform. Morgan Stanley also believes the case for biotech stocks is further reinforced by the financing environment and the outlook for mergers and acquisitions as well as upcoming innovation. The case for innovation Morgan Stanley also favors owning biotech stocks that have a strong drug platform even if the key catalyst of clinical trial data and FDA approvals are farther out. Rhythm ranks among the stocks rated overweight that Morgan Stanley favors in this category.

Persons: Morgan Stanley, Needham, Joseph Stringer, dealmaking, Stringer, erosive, it's, Phathom, GERD, LSEG, Merck, — CNBC's Michael Bloom Organizations: Federal Reserve, Nasdaq, Oncology, Immunology, Phathom Pharmaceutical, Pharmaceuticals, Phathom Pharmaceuticals, LSEG, Drug, Bristol Myers Squibb, Pfizer, Intellia Therapeutics, Rocket Pharmaceuticals Locations: New Jersey

But J&J's drug is walking away with a notable edge over its rival. They add more options to a growing arsenal of treatments that have helped improve outcomes for people with multiple myeloma. But the new approvals also give J&J's therapy, which was developed with Legend Biotech, a clear advantage over Bristol Myers's drug. J&J's drug has gradually gained ground over Abecma in the CAR-T market for multiple myeloma, even though it first entered the market a year later. With the new approval on Friday, Jefferies' Shi expects J&J's drug to win the majority of that market share.

Persons: Jonathan Raa, Johnson, Myers's, Bristol Myers, Jefferies, Kelly Shi, Shi, Carvykti, Cantor Fitzgerald, Rick Bienkowski, Kelsey Goodwin, Annika, annikakim.constantino@nbcuni.com Organizations: Nurphoto, Bristol Myers Squibb, Johnson, Food and Drug Administration, FDA, Legend Biotech, Bristol, New York Stock Exchange, NYSE, Reuters, Mount Sinai Hospital, Getty Locations: Bristol, U.S, EU, Japan, Mount Sinai, New York City

☆ Record levels of funding propel Denver-Boulder to the top of the life sciences market
▼ + stars: | 2024-04-08 | by ( Chris Dilella | ) www.cnbc.com time to read: +7 min

The Denver-Boulder region is rapidly emerging as a major hub for the life sciences industry, attracting companies that develop cutting-edge medical treatments and technologies. Life sciences research aims to understand living things, from cells to our planet, to improve health, food and the environment. Founded in 2003, the Bioscience Association supports the growth of life sciences, with a focus on access to capital, education, networking and more. A recent CBRE report found Denver-Boulder to be the top U.S. life sciences real estate market, fueled by record investment from venture capitalists and the National Institutes of Health. Entrepreneurial successThe recent surge in venture capital flowing into Denver-Boulder builds on the area's proven track record of success over the past several decades.

Persons: Tim Schoen, BioMed, Schoen, Elyse Blazevich, Kevin Koch, Koch, Edgewise, We've, Dan LaBarbera, LaBarbera, Dr Organizations: BioMed, CNBC, Blackstone, Flatiron, Enveda Biosciences, Denver, Boulder, Colorado Bioscience Association, Bioscience Association, National Institutes of Health, U.S, Pfizer, Therapeutics, University of Colorado, Edgewise Therapeutics, Research, University of Colorado's Anschutz Medical, Center, Drug, Center for Drug, for Drug, Anschutz Medical Locations: CNBC's, Denver, Boulder, Diego, Boulder , Colorado, San Diego, San Francisco, Seattle, Boston, Cambridge, Massachusetts, Aurora, Rocky, Colorado, Boulder ., Denver's

☆ Study links accelerated aging to cancer risk in younger adults
▼ + stars: | 2024-04-07 | by ( Brenda Goodman | ) edition.cnn.com time to read: +6 min

CNN —Researchers looking for clues about why some types of cancer are on the rise in younger adults say they’ve found an interesting lead: a connection to accelerated biological aging. What faster aging could tell us about cancer riskAfter adjusting the data for factors they thought might bias their results, the researchers found that accelerated aging was associated with increased risk for cancer. “There are medications that also look like they can slow down accelerated aging,” said Blaes, who is testing two of them in cancer survivors. Cancer survivors often show greater biological aging, perhaps because of the after effects of therapies like chemotherapy and radiation. It’s not quite prime time, where we would go out and prescribe those medications for people, but this is really, really important work,” Blaes said.

Persons: they’ve, It’s, ”, Yin Cao, Louis, Cao, Tian, ” Cao, Anne Blaes, “, Blaes, Dr, Sanjay Gupta, ” Blaes Organizations: CNN, Washington University School of Medicine, American Association of Cancer, University of Minnesota, Hematology, Oncology, UM, CNN Health, Cancer Locations: St, San Diego

☆ Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds
▼ + stars: | 2024-04-06 | by ( Jen Christensen | ) edition.cnn.com time to read: +8 min

The study, published Saturday in the New England Journal of Medicine, showed how the drug helped people with Type 2 diabetes who also had one of the most common kind of heart failure, obesity-related heart failure with preserved ejection fraction. Obesity-related heart failure with preserved ejection fraction can severely limit a person’s ability to participate in the activities of daily life. Often, people with type 2 diabetes who have this kind of heart failure have a more severe form than those who don’t have diabetes. People with a more severe form of heart failure sometimes don’t respond as well to medication as those with less severe disease. One death in the Wegovy group and four in the placebo group were related to cardiovascular issues.

Persons: Wegovy, Ozempic, Dr, Mikhail Kosiborod, “, ” Kosiborod, Naveed Sattar, ” Sattar, Sanjay Gupta, Kosiborod, ” Organizations: CNN, New England, of Medicine, Novo Nordisk –, US Food and Drug Administration, FDA, St, University of Glasgow, Science Media, CNN Health, American College of Cardiology Locations: Asia, Europe, North, South America, Kansas City , Missouri, Atlanta

☆ These stocks were oversold during this week's sell-off and could be due for a bounce
▼ + stars: | 2024-04-05 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

We used the CNBC Pro Stock Screener Tool to identify companies that are oversold based on their 14-day relative strength index. The stock is slightly oversold with a 14-day RSI reading of 24.52. Biopharmaceutical firm Biogen also made the list, with a 14-day RSI reading of 29.71. BIIB YTD mountain Biogen stock. Other oversold stocks on the list include Starbucks and Nike .

Persons: McDonald's, Krispy Kreme, Biogen, Wall, Baird, Brian P, Skorney Organizations: Dow Jones Industrial, Federal Reserve, CNBC, Israel, Starbucks, Nike Locations: Latin America

CNN —Rick Slayman, the world’s first living recipient of a genetically edited pig kidney transplant, was discharged from the hospital Wednesday, two weeks after his operation, Massachusetts General Hospital said in a statement. “He is recovering well and will continue to recuperate at home with his family,” the hospital said on X, formerly Twitter. Rick Slayman in his hospital room at Massachusetts General Hospital before his discharge on Wednesday April 3, 2024. Michelle Rose/Massachusetts General HospitalHis surgery is the third such xenotransplant of a pig organ into a living human. The first two transplants were hearts transplanted into living patients that had run out of other transplant options.

Persons: Rick Slayman, Slayman, I’ve, ”, Michelle Rose, Dr, Sanjay Gupta, ” Slayman Organizations: CNN, Massachusetts General Hospital, Massachusetts Department of Transportation, CNN Health, Procurement, Transplantation Network Locations: Massachusetts, U.S

Hedge fund managers gathered Wednesday at the 2024 Sohn Investment Conference in New York to share their best investment ideas. It kicked off with "Next Wave Sohn," a session that features ideas from rising stars within the hedge fund industry. Endocrinology is an $8 billion market, but the cumulative market size, including the company's future therapy targets, is upward of $200 billion, which includes estimates for future obesity drugs, the investor said. It has CA$75 billion market cap with an "unbelievable record of success," according to the investor. The short seller noted that the company has a $5 billion market cap with about $4.8 billion of debt.

Persons: Sohn, Eric Wolff, Wolff, Michelle Ross, Cushing, Ross, Eli Lilly, Crinetics, XBI, Nikhil Daftary, Alimentation, Daftary, Chris Drose, Nate Koppikar, Fahmi Quadir Organizations: Investment, Gumshoe Capital Management Investment, Pason Systems Energy, Pason Systems, Gumshoe Capital Management, StemPoint, Pharmaceuticals, Crinetics Pharmaceuticals, StemPoint Capital, Endocrinology, Novo Nordisk, P Biotech, NK Capital Investment, NK Capital, Starbucks, McDonalds, Bleecker Street Capital, Orso Partners, Justice Department, Federal Trade Commission, Safkhet, Global Education Locations: New York, Canada, U.S

☆ Enhanced Games Are Olympics With Steroids, Pay; Meet the Founder
▼ + stars: | 2024-03-31 | by ( Lloyd Lee | ) www.businessinsider.com time to read: +14 min

Several countries pay bonuses to medal winners, and high-profile athletes may get brand deals and sponsorships, but many Olympic athletes live quiet lives. AdvertisementD'Souza suggested he received funding for the Enhanced Games in the "single-digit millions" but declined to specify the amount. So far, it's unclear what kind of talent Enhanced Games will attract. He said that at the Enhanced Games, athletes would get comprehensive health checkups to monitor the effects of "whatever enhancement protocols" they're on and ensure they're fit to compete. D'Souza said he planned to announce more details about the Enhanced Games this summer — right around the Paris Olympics.

Persons: Aron D'Souza, gymgoers, D'Souza, Thomas Bach, Bach, Uber, Christian, Christian Angermayer, Balaji Srinivasan, Coinbase's, Peter Thiel, Angermayer, Srinivasan, Thiel, Hulk, Charles Harder, Harder, didn't, Sargon, Peter, VCs, Thiel hasn't, he's, James Magnussen, James, he'd, Marta Nawrocka, BI's Gabby Landsverk, Jim Walden, Grigory Rodchenkov, it's, who'd Organizations: International, Olympic, IOC, West Germany's Olympic, The New York Times, Business, Apeiron Investment, University of Melbourne, Gawker Media, BuzzFeed, Gawker, Abrams, Australian Financial, US, Doping Agency, UFC, Drug Free, NFL, NBA, MLB, Testing Agency, ITA, CNN, FBI, Sports, Gaming Initiative, Paris Locations: Miami, Lausanne, Switzerland, Oxford, Australian, Russia

☆ Texas appeals court blocks state from investigating families seeking gender-affirming care for trans youth
▼ + stars: | 2024-03-30 | by ( Emma Tucker | ) edition.cnn.com time to read: +6 min

CNN —A Texas appeals court upheld two injunctions in a pair of legal cases Friday, in an order blocking the state’s Department of Family and Protective Services from investigating families of transgender youth who are seeking gender-affirming medical care for their children. The court of appeals upheld a trial court decision in the Friday order, ruling in favor of LGBTQ+ advocates and families in two related Texas lawsuits asking a state court to block the agency from investigating parents who provide their children with gender-affirming care. Paxton appealed the district court injunction in March and declared investigations could continue during the appeal process under the law. The court, in its opinion, also affirmed Paxton’s opinion does not alter preexisting law or legal obligations of the department. Abbott’s directive to the agency was seen by many as an attack on transgender children and their families.

Persons: CNN —, Greg Abbott, Ken Paxton, Abbott, “, ”, Paxton, Bill, Chase Strangio, ” CNN’s Amir Vera, Ashley Killough Organizations: CNN, state’s Department of Family and Protective Services, Texas Gov, Republican, Department of Family and Protective Services, ”, Lambda Legal, ACLU, Texas Supreme, Gov, American Medical Association, American Psychiatric Association, American Academy of Pediatrics, HIV Locations: Texas, State of Texas, Travis County

☆ Ketamine Therapy Offers Hope for This Emergency Worker - The New York Times
▼ + stars: | 2024-03-26 | by ( Brandon Kapelow | ) www.nytimes.com time to read: +2 min

Emergency workers and researchers use the term “critical incident” to describe a traumatic event. I’ve been compelled to explore mental health issues — and their potential solutions — ever since. Research has found that throughout a career, an emergency worker may experience over 180 critical incidents. While observing emergency workers in this documentary, I was amazed by their ability to work so calmly through crises and transition quickly in and out of their home lives. I wrote previously that the American West has some of the nation’s worst outcomes for behavioral health issues such as substance abuse and suicide.

Persons: I’ve, psychotherapies Organizations: Research, American Foundation for Suicide, Department of Veterans Affairs Locations: American, Wyoming, psychedelics

☆ Why Nora Turato is taking on the wellness industry
▼ + stars: | 2024-03-26 | by ( Victoria Woodcock | ) edition.cnn.com time to read: +6 min

stop lying!” — a solo show at Sprüth Magers’ Los Angeles gallery, and a riposte to the wellness industry. Robert Wedemeyer/Courtesy Sprüth MagersAt the latter in 2022, she performed her one-woman “pool 5” monologue live more than 20 times over a two-week period. Born in Zagreb, Turato refers to her home country as “very in-between — not really eastern Europe; not really west,” she said. Robert Wedemeyer/Courtesy Sprüth MagersFor Sprüth Magers co-founder Philomene Magers, “Nora’s work puts people in front of a mirror,” she said. Tellingly, Turato’s self-optimization journey has ended in digital detox.

Persons: Nora Turato, “, ”, Zoom, Robert Wedemeyer, Barbara Kruger, —, Magers, Philomene Magers, it’s, haha, Turato, Julie Adams, It’s, — “, You’ve, “ I’ve Organizations: CNN, YouTube, Museum of Modern Art, Hollywood, Systems, “ Locations: Croatian, Los Angeles, Amsterdam, New York, Zagreb, Croatia, Arnhem, Netherlands, Turato, Europe, ”, LA

☆ FDA approves Merck's drug for rare, deadly lung condition
▼ + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The condition refers to when the small blood vessels in the lungs narrow. He noted that the drug will be a "paradigm shift" for patients living with PAH. That includes reducing the risk of death or worsening of the condition by 84% compared to an existing drug alone. Those trials include late-stage studies on patients with more advanced PAH disease, and those who are within the first year after diagnosis.

Persons: Chris Schott, Eliav Barr, PAH, Barr, Merck Organizations: Merck, Drug Administration, JPMorgan, CNBC, Acceleron Pharma Locations: Rahway , New Jersey, U.S, Winrevair

☆ FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a ‘ticking time bomb’
▼ + stars: | 2024-03-26 | by ( Brenda Goodman | ) edition.cnn.com time to read: +15 min

These proteins cause the walls of a person’s blood vessels to keep growing and thicken over time. As the blood vessels narrow, the heart is forced to work harder to pump blood to the lungs. Treatment with a combination of drugs that dilate, or relax, blood vessels can improve this outlook, but they are not a cure. Both groups were also taking the standard medications for the condition, which help relax blood vessels to improve blood flow. But Galiatsatos said that as promising as the drug looks, there are still many unknowns, including whether the drug will benefit all PAH patients equally.

Persons: Katrina Barry, Barry, “, ”, Winrevair, Merck Winrevair, Vallerie McLaughlin, Panagis, Galiatsatos, isn’t, ” Barry, I’m, fanny, She’s, sotatercept, PAH, Sotatercept, “ There’s, Kristin Highland, Highland, ” Merck, Merck, Dr, Sanjay Gupta, Aaron Waxman, Barry’s, he’s, they’ve, Johnson –, Waxman, “ I’ve, “ It’s, who’ve Organizations: CNN, American Lung Association, US Food and Drug Administration, Merck, FDA, University of Michigan, PAH, Johns Hopkins Bayview Medical Center, New England, of Medicine, Cleveland Clinic, Institute, Clinical, CNN Health, Brigham, Women’s Hospital, Johnson Locations: PAH, American, Greece, Boston

☆ Novo Nordisk strikes deal worth up to $1.1 billion to expand cardio business
▼ + stars: | 2024-03-25 | by ( ) www.cnbc.com time to read: +1 min

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Denmark's Novo Nordisk said on Monday it had agreed to buy Cardior Pharmaceuticals for up to 1.03 billion euros ($1.1 billion) to strengthen its cardiovascular pipeline. The deal is in line with Novo's aim to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments. The Danish company has rocketed to become one of the world's most valuable companies on the back of its hugely popular weight-loss treatment Wegovy. The deal includes Cardior's lead compound CDR132L, currently in intermediate Phase II clinical trials for the treatment of heart failure, Novo said.

Persons: Novo, CDR132L Organizations: Novo Nordisk, Denmark's, Nordisk, Cardior Pharmaceuticals Locations: Bagsvaerd, Copenhagen, Denmark, Danish, Novo

☆ Opinion: Trump’s image is on the line
▼ + stars: | 2024-03-24 | by ( Richard Galant | ) edition.cnn.com time to read: +20 min

We’re looking back at the strongest, smartest opinion takes of the week from CNN and other outlets. … Deals are my art form.”Having a lot of money distinguished him from other presidential candidates, Trump contended. ‘I don’t need anybody’s money,’ Trump said in his June 2015 presidential campaign announcement.”“Now Trump needs money, a lot of it. In July 2006, she met Trump at a celebrity golf tournament and says that the two had sex that weekend. “Whatever the Fifth Circuit and Supreme Court decide next, the question for President Joe Biden is what to do now,” wrote Lawrence Downes.

Persons: Charles Dickens, “ David Copperfield, Micawber, ” Micawber, “, Dickens, Donald Trump, Letitia James, Trump, he’ll, ”, Tony Schwartz, I’ve, Frida Ghitis, ’ Trump, … Dana Summers, Joe Biden’s, Julian Zelizer, Biden’s, ” Bill Bramhall, Stormy Daniels, Peacock, Ana Marie Cox, Daniels, she’s, Peter Navarro, He’s, Mike Johnson, Kevin McCarthy, House Republicans —, Matt Gaetz ’, Marjorie Taylor Greene, Johnson, Clay Jones, Paul Sracic, Fareed Zakaria, Biden, Peter Bergen, Bashar al, Assad, ” Bergen, Vladimir Putin, Richard Aboulafia, ” David Horsey, Joann, Lynda Gorov, it’s, ” Kate Middleton’s, Princess, Wales, Sara Stewart, Kate, that’s, she’ll, Joe Biden, Lawrence Downes, “ Biden, Greg, Abbott, ’, ” Downes, Trump’s, Jared Kushner, Kushner, Donald Trump’s, Aseel Mousa, Drew Sheneman, Max Besbris, ” Besbris, Linda Thomas, Greenfield, Thomas, Eleanor Roosevelt, ‘, ” Don’t, Grace Elizabeth Hale, Elizabeth Yuko, Avi Weiss, Jennifer Jones, Jill Filipovic, Christine Blasey Ford Derrick Johnson, Peter Rutland, Holly Thomas, Lily Allen, Mary Ziegler, Lanhee Chen, Steve Garvey, Adam Schiff, Patricia Grisafi, Caitlin Clark Walt Handelsman, Caitlin Clark, Amy Bass, Kamilla Cardoso, UCLA’s Kiki Rice, ’ ” Clark, Bass, Pete ’ Maravich, Court, Serena Williams, Clark, Maravich …, — Organizations: CNN, New, Trump, Agency, Twitter, Save, Maga Inc, Biden, Content Agency Trump, House Republicans, Rep, Ohio GOP, Russia ISIS, ISIS, Boeing, Airbus, Crafts, Boys, BBC Studios, Circuit, Texas Gov, Abbott, of Justice, Texans, Harvard, National Association of Realtors, United Nations, “, University of Iowa, ESPN, Iowa Hawkeyes, NCAA Division Locations: Save America, New York, Baton Rouge , Louisiana, Ohio, Russia, Moscow, Iraq, Syria, Syrian, “, Iran, Afghanistan, ”, Ukrainian, Windsor, ” Texas, Texas, Gaza, Southern, Rafah, Egypt, Israel, Gaza City, Al, Grace Elizabeth Hale : Mississippi, ‘, California

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

☆ Elon Musk suggests his prescription ketamine use is good for investors
▼ + stars: | 2024-03-18 | by ( Daniel Arkin | ) www.cnbc.com time to read: +5 min

In a new interview, Elon Musk said prescription ketamine has been helpful in treating his occasional depressive episodes and suggested that taking the drug has been beneficial for investors in his companies. Musk was asked by Lemon whether ketamine could "get in the way" of his government contracts and his standing on Wall Street. Musk added that he originally mentioned his prescription ketamine use on X "because I thought, maybe this is something that could help other people." Lemon asked Musk whether he ever "abuses" ketamine, which the billionaire said he is taking under a doctor's supervision. In a short introduction to the Musk interview, Lemon said that he did not know exactly why Musk had decided to scrap their deal.

Persons: Elon Musk, Don Lemon, Lemon, Musk, X, Tulsi Gabbard, Jim Rome, Matthew Perry, Musk's, Chloe Melas, whatever's, I'm Organizations: CNN, SpaceX, Tesla, Wall Street, YouTube, Spotify, NBC Locations: Gruenheide, Berlin, Germany, Austin , Texas, Hawaii

Search resuls for: "Therapies"

25 mentions found